Your lab partner for somatic and germline testing
As a provider of comprehensive laboratory services, we offer testing solutions that span the continuum of care for a holistic view of the patient. We connect genetic insights from patients, clinical trials and health systems to help cancer care teams navigate the complex treatment landscape and provide personalized care.
Unlock personalized care for patients with solid tumors
Screening and Risk Assessment - Diagnostic and Prognostic – Therapy Selection – Monitoring
Labcorp Plasma Detect
A portfolio of highly sensitive tumor-informed solutions for detection of molecular residual disease (MRD)
OmniSeq® INSIGHT: A tissue-based comprehensive genomic solution with a 7-10 day turnaround time
Now includes homologous recombination deficiency (HRD) status and genomic instability score (GIS) to support confident, personalized treatment planning.
Informs on therapy selection and clinical trial eligibility through a multimodal approach that evaluates biomarker status across 500+ genes, tumor mutational burden (TMB), microsatellite instability (MSI), PD-L1, and BRCA1/2-related HRD markers.
Labcorp Plasma Complete: A liquid biopsy-based pan-tumor profiling test
A tumor profiling solution when tissue is insufficient or not available. This ctDNA-based comprehensive genomic profiling assay reports on biomarker status across 521 genes including microsatellite instability (MSI)
FDA authorized kitted CGP assays to enable localized testing with PGDx elio tissue complete and PGDx elio plasma focus Dx
Bring comprehensive genomic profiling (CGP) in-house with just a simple verification step, providing faster results, full control of sample chain of custody and complete data ownership.
Germline Testing for risk assessment and provide increased insights to inform on treatment path with Invitae® Hereditary Cancer Panels
Germline genetic testing identifies inherited cancer risk and guides personalized screening, prevention and treatment strategies for patients and their families.